Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Dr Mark Verrill studied Medicine at the University of Cambridge and University College London, qualifying in 1989. He was awarded Membership of the Royal College of Physicians in 1993 and Fellowship in 2003. He trained in medical oncology at the Royal Marsden Hospital and Institute of Cancer Research, London.
Dr Verrill's first consultant appointment in 1989 was as Cancer Research UK Senior Lecturer in Medical Oncology at Newcastle University and Honorary Consultant Medical Oncologist in the Newcastle Hospitals. He moved full time into the NHS in 2007.
Dr Verrill is internationally respected for his clinical trials work in breast cancer and regarded as a "key opinion leader" with multiple publications in high impact peer-reviewed journals. He's also lectured on breast cancer all over the world. His areas of interest include Systemic therapies for Breast Cancer, HER2 positive breast cancer, ER positive breast cancer and Gastrointestinal Stromal Tumours.
American Society of Clinical Oncology
Association of Cancer Physicians
British Association for Cancer Research
Dr Mark Verrill does not hold a share or financial interest in the Rutherford Cancer Centres or another Rutherford Health plc company.
Dr Mark Verrill does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Rutherford Health plc company.
Dr Mark Verrill does not hold any paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Rutherford Health plc.